

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED**  
**紛美包裝有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00468)**

- (1) FURTHER DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND THE 2025 INTERIM RESULTS;**  
**(2) PUBLICATION OF UNAUDITED MANAGEMENT ACCOUNTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025; AND**  
**(3) CONTINUED SUSPENSION OF TRADING**

**INTRODUCTION**

This announcement is made by Greatview Aseptic Packaging Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Reference is made to (i) the announcement of the Company dated 28 February 2025 (the “**28 February Announcement**”) in relation to, among other matters, the establishment of the special investigation committee to undertake an independent investigation (the “**Special Investigation**”); (ii) the announcements of the Company dated 25 March 2025, 30 April 2025, 16 May 2025, 13 June 2025, 31 July 2025 and 22 August 2025 (the “**22 August Announcement**”) in relation to, among other matters, the delay in publication of the 2024 Annual Results, suspension of trading in the Company’s shares on the Stock Exchange and the Resumption Guidance; and (iii) the announcement of the Company dated 2 October 2025 (the “**2 October Announcement**”) in relation to, among other matters, key findings of the independent investigation report regarding the Special Investigation. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the aforementioned announcements.

## **FURTHER DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND THE 2025 INTERIM RESULTS; FURTHER POSTPONEMENT OF BOARD MEETING AND DELAY IN DESPATCH OF THE 2024 ANNUAL REPORT AND 2025 INTERIM REPORT**

In the 22 August Announcement, it was disclosed that the Company expected the 2024 Annual Results would be published by 31 October 2025, and the 2025 Interim Results would be published by 28 November 2025.

As further disclosed in the 2 October Announcement, the Special Investigation Committee has recommended the Board to consider the findings of the Report and the appropriate next steps. In view of the aforesaid outstanding items in connection with the Special Investigation, the Auditors are unable to complete the audit of the 2024 Annual Results by 31 October 2025. Accordingly, the Company anticipates that the 2024 Annual Results will not be published before 31 October 2025.

In addition, due to the further delay in publication of the 2024 Annual Results, the Company expects that the 2025 Interim Results will not be published on or before 28 November 2025.

The Company is working closely with the relevant professional parties with a view to resolving the outstanding work and completing the audit of the 2024 Annual Results as soon as practicable. As at the date of this announcement and taking into account the current situation, it is expected that the 2024 Annual Results will be published by 31 December 2025, subject to the completion of all audit work as agreed with the Auditors and all of the outstanding items as mentioned above having been resolved. Assuming the 2024 Annual Results are published on or before 31 December 2025, it is expected that (i) the 2025 Interim Results will be published on or before 31 January 2026; (ii) the 2024 Annual Report will be published on or before 31 December 2025; and (iv) the 2025 Interim Report will be published on or before 31 January 2026.

## **PUBLICATION OF THE UNAUDITED MANAGEMENT ACCOUNTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025**

In order to keep the Shareholders and potential investors of the Company informed of the Group's business operations and financial position, the Company would like to provide the Shareholders and potential investors of the Company with preliminary unaudited financial information of the Group for the nine months ended 30 September 2025 (prepared on the basis of the Deconsolidation), which was extracted from the management accounts of the Group for the nine months ended 30 September 2025, together with the comparative figures for the corresponding period in 2024.

	<b>Nine months ended</b>	
	<b>30 September</b>	
	<b>2025</b>	<b>2024</b>
	<b>RMB'000</b>	<b>RMB'000</b>
	<b>(Unaudited)</b>	<b>(Unaudited)</b>
<b>Continuing operations</b>		
Revenue	1,409,527	1,598,715
Cost of sales	<u>(1,191,771)</u>	<u>(1,311,101)</u>
<b>Gross profit</b>	<b>217,756</b>	287,614
Other income	37,539	42,797
Other (losses)/gains - net	(3,596)	2,024
Impairment losses on financial assets	(6,215)	(4,500)
Fair value gains on financial assets at fair value through profit or loss (“FVTPL”)	9,417	279
Share of profit of associates	25,932	41,075
Distribution expenses	(44,550)	(46,026)
Administrative expenses	<u>(119,408)</u>	<u>(127,193)</u>
<b>Operating profit</b>	<b>116,875</b>	196,070
Finance costs	<u>(1,420)</u>	<u>(3,271)</u>
<b>Profit before income tax</b>	<b>115,455</b>	192,799
Income tax expense	<u>(38,473)</u>	<u>(35,794)</u>
<b>Profit for the period from continuing operations</b>	<u><b>76,982</b></u>	<u>157,005</u>
<b>Discontinued operations</b>		
Profit for the period from discontinued operations	<u>–</u>	<u>31,344</u>
<b>Profit for the period</b>	<u><b>76,982</b></u>	<u>188,349</u>
<b>Profit for the period attributable to equity owners of the Company:</b>		
– From continuing operations	76,982	157,005
– From discontinued operations	<u>–</u>	<u>31,344</u>
	<u><b>76,982</b></u>	<u>188,349</u>

	<b>Nine months ended</b>	
	<b>30 September</b>	
	<b>2025</b>	2024
	<b>RMB'000</b>	RMB'000
	<b>(Unaudited)</b>	(Unaudited)
<b>Other comprehensive (expense)/income:</b>		
Item that may be reclassified to profit or loss		
Currency translation differences	<b>12,974</b>	(5,944)
Share of other comprehensive expense of associates, net of related income tax		
Exchange difference released upon disposal of subsidiaries		
Equity investments designated at fair value through other comprehensive income: – Changes in fair value	<u><b>57,877</b></u>	<u>–</u>
<b>Total comprehensive income for the period</b>	<b>147,833</b>	182,405
<b>Total comprehensive income attributable to:</b>		
Owners of the Company	<b>147,833</b>	182,405
Non-controlling interests	<u>–</u>	<u>–</u>
	<u><b>147,833</b></u>	<u>182,405</u>

	As at <b>30 September</b> <b>2025</b> <i>RMB'000</i> (Unaudited)	As at 31 December 2024 <i>RMB'000</i> (Unaudited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	<b>616,337</b>	670,765
Right-of-use assets	<b>39,719</b>	43,914
Interests in associates	–	425,130
Other equity instruments investments	<b>521,914</b>	–
Financial assets at FVTPL	<b>549,788</b>	541,041
Intangible assets	<b>54,170</b>	54,153
Deferred income tax assets	<b>40,881</b>	36,523
Trade receivables	<b>195,747</b>	61,216
Prepayments	<b>115</b>	1,189
	<b><u>2,018,671</u></b>	<u>1,833,931</u>
<b>Current assets</b>		
Inventories	<b>470,533</b>	586,842
Trade and notes receivables	<b>539,273</b>	570,316
Prepayments	<b>7,700</b>	18,366
Other receivables	<b>40,651</b>	7,889
Contract assets	<b>6,826</b>	–
Financial assets at FVTPL	<b>104,718</b>	–
Amount due from an associate	–	11,919
Restricted cash	<b>156,752</b>	135,236
Cash and cash equivalents	<b>339,077</b>	748,255
	<b><u>1,665,530</u></b>	<u>2,078,823</u>
Total assets	<b><u>3,684,201</u></b>	<u>3,912,754</u>
<b>EQUITY</b>		
<b>Capital and reserves attributable to equity holders of the Company</b>		
Share capital, share premium and capital reserve	<b>603,809</b>	603,809
Statutory reserve	<b>339,947</b>	339,947
Exchange reserve	<b>(61,920)</b>	(74,894)
Other comprehensive income	<b>57,877</b>	–
Retained earnings	<b>2,130,644</b>	2,254,163
	<b><u>3,070,357</u></b>	<u>3,123,025</u>
<b>Total equity</b>	<b><u>3,070,357</u></b>	<u>3,123,025</u>

	As at 30 September 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Unaudited)
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Deferred government grants	6,101	7,295
Lease liabilities	626	4,412
Deferred income tax liabilities	<u>1,675</u>	<u>16,863</u>
	<u>8,402</u>	<u>28,570</u>
<b>Current liabilities</b>		
Deferred government grants	1,574	1,519
Contract liabilities	7,634	16,074
Trade payables, other payables and accruals	572,980	648,671
Income tax liabilities	22,235	17,465
Borrowings	–	76,462
Lease liabilities	<u>1,019</u>	<u>968</u>
	<u>605,442</u>	<u>761,159</u>
<b>Total liabilities</b>	<u>613,844</u>	<u>789,729</u>
<b>Total equity and liabilities</b>	<u>3,684,201</u>	<u>3,912,754</u>
<b>Net current assets</b>	<u>1,060,088</u>	<u>1,317,664</u>
<b>Total assets less current liabilities</b>	<u><u>3,078,759</u></u>	<u><u>3,151,595</u></u>

The Board wishes to emphasise that the unaudited financial information set out above is subject to, among others, further review by the Company and any potential adjustments to the 2024 Annual Results that might be proposed by the Auditors (and any corresponding changes required to be made to the 2025 Interim Results and unaudited financial information of the Group for the nine months ended 30 September 2025), and has not been reviewed by the Audit Committee, nor has it been reviewed, audited or approved by the Auditors. The unaudited financial information above is only based on the preliminary assessment by the Board on the unaudited management accounts of the Group for the nine months ended 30 September 2025, and is not based on any data or information that has been audited, reviewed or approved by the Auditors, the Audit Committee or the Company. The unaudited financial information will be subject to changes resulting from, among others, further review by the Company and any

**adjustments that may be made by the Auditors subject to the completion of the auditing process. The Board cannot guarantee the unaudited financial information set out above truly reflects the financial performance and condition of the Group and such information might be misleading if any potential adjustments have not been taken into account.**

**Shareholders and potential investors should exercise extreme caution when considering the unaudited financial information disclosed above and when dealing in the shares of the Company.**

## **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 19 February 2025 and will remain suspended until further notice.

Further announcement(s) will be made by the Company as and when appropriate and in accordance with the requirements of the Listing Rules and the Resumption Guidance to keep its shareholders and potential investors informed of (i) the resumption progress; (ii) the publication of the 2024 Annual Results and the 2025 Interim Results; (iii) the despatch of the 2024 Annual Report and the 2025 Interim Report; (iv) the date of the board meeting for the purposes of considering and approving, among other matters, the 2024 Annual Results and the 2025 Interim Results; and (v) the convention of the annual general meeting of the Company.

By order of the Board  
**Greatview Aseptic Packaging Company Limited**  
**YUAN Xunjun**  
*Chairman and Executive Director*

Beijing, the People's Republic of China, 27 October 2025

*As at the date of this announcement, the Board comprises two executive directors, namely, Mr. YUAN Xunjun and Mr. LEE Hsien Dar Victor; five non-executive directors, namely, Ms. WANG Ziting, Ms. WANG Yingli, Mr. CHOI Sum Shing Samson, Mr. YUEN Kai Yiu Kelvin and Mr. LI Weijin; and four independent non-executive directors, namely Ms. KOU Chung Yin Mariana, Mr. TANG Poon Tung Denny, Mr. CHOI Wai Hong Clifford and Mr. CHEN Qi.*